Cytokinetics (NASDAQ:CYTK) Given New $112.00 Price Target at Needham & Company LLC

Cytokinetics (NASDAQ:CYTK) had its target price increased by Needham & Company LLC from $102.00 to $112.00 in a research report report published on Friday morning, Marketbeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. UBS Group raised shares of Cytokinetics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $69.00 to $115.00 in a report on Monday, June 29th. Stifel Nicolaus lifted their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley upped their price objective on shares of Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Citigroup restated a “market outperform” rating on shares of Cytokinetics in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.85.

Cytokinetics Trading Down 5.7%

Shares of CYTK stock opened at $76.76 on Friday. Cytokinetics has a twelve month low of $32.89 and a twelve month high of $88.31. The stock has a market cap of $9.55 billion, a P/E ratio of -10.63 and a beta of 0.38. The stock has a 50 day moving average of $78.91 and a 200 day moving average of $70.90.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.12) EPS. On average, research analysts predict that Cytokinetics will post -6.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In other news, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total value of $636,900.00. Following the sale, the chief executive officer owned 377,830 shares in the company, valued at $32,085,323.60. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the transaction, the executive vice president owned 58,555 shares of the company’s stock, valued at approximately $4,337,754.40. This trade represents a 20.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,179 shares of company stock valued at $9,126,054 over the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

A number of institutional investors have recently made changes to their positions in CYTK. Vanguard Group Inc. lifted its holdings in Cytokinetics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after purchasing an additional 191,336 shares in the last quarter. State Street Corp raised its position in shares of Cytokinetics by 3.7% in the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after buying an additional 207,961 shares during the last quarter. Deep Track Capital LP lifted its stake in shares of Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after buying an additional 650,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Cytokinetics by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after buying an additional 15,815 shares in the last quarter. Finally, Vestal Point Capital LP boosted its position in Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after acquiring an additional 384,469 shares during the last quarter.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.